485 related articles for article (PubMed ID: 31608053)
1. A Retrospective Study of Patient-Reported Data of Bullous Pemphigoid and Mucous Membrane Pemphigoid From a US-Based Registry.
Lee J; Seiffert-Sinha K; Attwood K; Sinha AA
Front Immunol; 2019; 10():2219. PubMed ID: 31608053
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.
Amber KT; Murrell DF; Schmidt E; Joly P; Borradori L
Clin Rev Allergy Immunol; 2018 Feb; 54(1):26-51. PubMed ID: 28779299
[TBL] [Abstract][Full Text] [Related]
3. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.
Bohelay G; Alexandre M; Le Roux-Villet C; Sitbon I; Doan S; Soued I; Shourick J; Rousset L; Mellottee B; Heller M; Lièvre N; Zumelzu C; Morin F; Grootenboer-Mignot S; Gabison E; Caux F; Prost-Squarcioni C; Musette P
Front Immunol; 2022; 13():915205. PubMed ID: 35844526
[TBL] [Abstract][Full Text] [Related]
4. Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis.
Yayli S; Pelivani N; Beltraminelli H; Wirthmüller U; Beleznay Z; Horn M; Borradori L
Br J Dermatol; 2011 Nov; 165(5):1133-7. PubMed ID: 21711326
[TBL] [Abstract][Full Text] [Related]
5. New immunomodulating drugs in autoimmune blistering diseases.
Korman NJ
Dermatol Clin; 2001 Oct; 19(4):637-48, viii. PubMed ID: 11705351
[TBL] [Abstract][Full Text] [Related]
6. Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
Russo R; Cozzani E; Gasparini G; Parodi A
Dermatol Ther; 2020 Jan; 33(1):e13190. PubMed ID: 31863534
[TBL] [Abstract][Full Text] [Related]
7. Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA.
Bekou V; Thoma-Uszynski S; Wendler O; Uter W; Schwietzke S; Hunziker T; Zouboulis CC; Schuler G; Sorokin L; Hertl M
J Invest Dermatol; 2005 Apr; 124(4):732-40. PubMed ID: 15816831
[TBL] [Abstract][Full Text] [Related]
8. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
Front Immunol; 2018; 9():1030. PubMed ID: 29881377
[TBL] [Abstract][Full Text] [Related]
9. [Involvement of mucous membranes in autoimmune bullous diseases].
Günther C
Hautarzt; 2016 Oct; 67(10):774-779. PubMed ID: 27631412
[TBL] [Abstract][Full Text] [Related]
10. Immune-mediated subepithelial blistering diseases of mucous membranes. Pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by antigenic specificity of autoantibodies.
Chan LS; Yancey KB; Hammerberg C; Soong HK; Regezi JA; Johnson K; Cooper KD
Arch Dermatol; 1993 Apr; 129(4):448-55. PubMed ID: 7682049
[TBL] [Abstract][Full Text] [Related]
11. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.
Santi CG; Gripp AC; Roselino AM; Mello DS; Gordilho JO; Marsillac PF; Porro AM
An Bras Dermatol; 2019 Apr; 94(2 Suppl 1):33-47. PubMed ID: 31166405
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of the long-term therapeutic effectiveness and safety profile of rituximab in the treatment of mucous membrane pemphigoid in a German university center between 2008 and 2019.
Bamberger F; König IR; Gola D; Zillikens D; Sadik CD
Front Immunol; 2023; 14():1180150. PubMed ID: 37143653
[TBL] [Abstract][Full Text] [Related]
13. Dual diagnosis of Pemphigus and pemphigoid. Retrospective review of thirty cases in the literature.
Sami N; Ahmed AR
Dermatology; 2001; 202(4):293-301. PubMed ID: 11455140
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
Daoud YJ; Amin KG
Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
[TBL] [Abstract][Full Text] [Related]
15. Bullous and cicatricial pemphigoid.
Anhalt GJ; Morrison LH
J Autoimmun; 1991 Feb; 4(1):17-35. PubMed ID: 2031659
[TBL] [Abstract][Full Text] [Related]
16. Development of pemphigus foliaceus in a mucous membrane pemphigoid patient: An insight into possible mechanism eliciting a distinct autoimmune bullous disease in a rare anti-basement membrane autoimmunity.
Shimoda-Komatsu Y; Fukui K; Yamazaki Y; Ohyama M
J Dermatol; 2021 May; 48(5):710-714. PubMed ID: 33725421
[TBL] [Abstract][Full Text] [Related]
17. Cicatricial pemphigoid, bullous pemphigoid, and epidermolysis bullosa acquisita antigens: differences in organ and species specificities and localization in chemically-separated human skin of three basement membrane antigens.
Fine JD
Coll Relat Res; 1985 Sep; 5(4):369-77. PubMed ID: 3902344
[TBL] [Abstract][Full Text] [Related]
18. Frequency of IgA antibodies in pemphigus, bullous pemphigoid and mucous membrane pemphigoid.
Cozzani E; Drosera M; Parodi A; Carrozzo M; Gandolfo S; Rebora A
Acta Derm Venereol; 2004; 84(5):381-4. PubMed ID: 15370705
[TBL] [Abstract][Full Text] [Related]
19. [Anti-p200 pemphigoid: Remission under mycophenolate mofetil (Cellcept®)].
Raffin D; Delaplace M; Roussel A; Estève E
Ann Dermatol Venereol; 2013 Dec; 140(12):784-7. PubMed ID: 24315224
[TBL] [Abstract][Full Text] [Related]
20. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP).
Maley A; Warren M; Haberman I; Swerlick R; Kharod-Dholakia B; Feldman R
J Am Acad Dermatol; 2016 May; 74(5):835-40. PubMed ID: 26936298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
